Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on December 23, 2016, regarding events occurring on December 19, 2016. The filing details the entry into a material definitive agreement for a private placement offering of equity securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $10 million.
- Securities Issued: Approximately 5.2 million Units.
- Unit Composition: One share of Common Stock and one Investor Warrant per Unit.
- Price per Unit: $1.915.
- Warrant Exercise Price: $1.79 per share.
- Warrant Terms: Non-exercisable for six months; expire three years from issuance.
- Placement Agent Fees: 7.5% of gross proceeds in cash plus a warrant to purchase 4% of the shares sold in the Offering.
- Insider Participation: Three executive officers/directors agreed to purchase 295,000 Units for an aggregate price of $564,925.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement to sell Units to accredited investors. A Registration Rights Agreement was also executed, requiring the Company to file a registration statement for resale of the securities within 30 days of closing and to have it become effective within 120 days. Failure to meet these deadlines triggers liquidated damages of 1% of the invested amount per 30-day period, capped at 10%.
Outlook, Risks, and Contingencies
- Closing Date: Expected by December 28, 2016.
- Regulatory Status: The offering is exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
- Indemnification: The Company agreed to indemnify investors against liabilities arising from breaches of representations or actions related to the Offering.
- Financial Impact: The filing does not provide specific data on the Company's current revenue, profit, cash flow, or debt levels prior to this transaction.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $10 million gross proceeds.
- Confirm the filing and effectiveness date of the registration statement for resale.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Assess the dilution impact of the 5.2 million new shares and associated warrants on existing shareholders.
- Check subsequent filings for the Company's cash position post-closing to determine liquidity improvement.